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Idarubicin (IDR) is a daunorubicin derivative frequently used in
the treatment of haematological malignancies. Like other anthra-
cyclines, IDR exerts its action by intercalating DNA and inhibiting
topoisomerase II (Liu et al, 1983). In vitro studies and in vivo
preclinical models showed IDR to be more cytotoxic than
daunorubicin or doxorubicin (Salmon et al, 1981; Broggini et al,
1984; Dodion et al, 1987; Schott et al, 1989). Idarubicinol
(IDRol), an alcohol metabolite present in large amounts in plasma
after administration of IDR, is similarly cytotoxic in vitro as the
parent compound, in contrast with other anthracyclines which
metabolites have only a low cytotoxic effect. This peculiar charac-
teristic of IDRol must probably be ascribed to its lipophilicity,
which allows easier penetration into the cell (Kuffel et al, 1992).
The first evidence of IDR clinical activity was established in the
treatment of patients with relapsed or refractory acute myeloge-
nous leukemia (Vogler et al, 1992). More recently, clinical trials
have demonstrated its activity in other malignancies such as the
myelodysplastic syndromes (Greenberg et al, 1993), multiple
myeloma (Chisesi et al, 1988) and advanced breast cancer
(Twelves et al, 1995). Furthermore, IDR induced a high response
rate (43%) in patients with relapsed or refractory
intermediate–high-grade non-Hodgkin’s lymphoma, with more
than 10-months median duration of response (Case et al, 1993). In
combination with other chemotherapeutic agents, IDR achieved
response rates ranging from 47% to 80% with 7–12 months
median duration of response (Dufour et al, 1993; Engert et al,
1995; Garay et al, 1997). We therefore decided to substitute mito-
xantrone with IDR for patients with lymphoma undergoing high-
dose chemotherapy and autologous stem cell transplantation
according to the high-dose sequential protocol developed by
Gianni et al (1993). In this scheme, high-dose IDR was associated
with high-dose melphalan as conditioning regimen before autolo-
gous haematopoietic stem cell transplantation. The addition of
anthracyclines to the conditioning regimen for bone marrow trans-
plantation is associated with severe oral mucositis and slower
haematopoietic recovery. These side-effects seem to be schedule-
dependent and can be partially avoided when IDR is given as a
continuous infusion between days –12 and –11 prior to bone
marrow transplantation compared with days –7 and –1. Moreover,
it was hypothesized that delayed engraftment may be due to the
presence of IDR and its active metabolite IDRol at the time of the
graft infusion and during the early post-transplant days, because of
the very long half-life of these substances (Van Der Lely et al,
1989; Muus et al, 1993). Pharmacokinetic studies indicate in fact
that the half-life of IDR and IDRol after oral administration ranges
between 5 and 39 h and between 13 and 64 h respectively with a
median value of 13.7 and 45.8 h. Similarly, median values of 
16.2 h for IDR and of 54.4 h for IDRol were observed after intra-
venous administration (Camaggi et al, 1992; Robert et al, 1993).
It is believed that reinfusion of stem cells should be delayed
until plasma concentrations of the drug and its active metabolite
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cells, but to date there are no data comparing IDRol plasma
concentration to haematopoietic stem cell toxicity. We therefore
planned to study IDR and IDRol cytotoxicity first on clonogeneic
cells derived from human umbilical cord blood (HCB), then on
peripheral blood progenitor cells (PBPC) from mobilized patients.
Furthermore, we evaluated the inhibitory activity on CFUs growth
of plasma samples collected from IDR treated patients at the time
of transplantation and we correlated this inhibitory capacity with
the time to engraftment.
PATIENTS AND METHODS
Cells
HCB samples were obtained after informed consent of the mother
from normal vaginal deliveries. In all cases 40–50 ml of HCB
were collected in sterile heparin-containing tubes, stored at +4°C
and processed within 24 h. Mononuclear cells (MNC) were sepa-
rated using a Ficoll gradient and depleted of adherent cells by
overnight incubation in IMDM–20% fetal bovine serum (FBS) at
37°C, 5% carbon dioxide. Cells were cryopreserved in aliquots and
stored in liquid nitrogen until use. In order to verify that HCB drug
sensitivity can be predictive of the PBPC sensitivity, we tested
MNC obtained from leukapheresis products (AP). AP mononuclear
cells were separated by density centrifugation, depleted of adherent
cells, cryopreserved and stored as described above.
Cytotoxic treatment of haematopoietic cells
We tested IDR, IDRol and doxorubicin as a reference compound.
All drugs, provided by Pharmacia and Upjohn (Milan, Italy), were
reconstituted in sterile water and the concentration of the solutions
were verified by high-performance liquid chromatography
(HPLC). Aliquoted drugs were stored at –80°C until use. After
thawing, HCB and AP mononuclear cells were incubated for 1 h or
24 h at 37°C in a 1 ml final volume of serum-free IMDM
containing the drug at the concentration to be tested. After washing
twice with IMDM–10% FBS, cells were plated in clonogeneic
assays. For each drug, a first set of four experiments was set up at
concentrations ranging over five logs; in a second set of experi-
ments doses were chosen within the ID10–ID90 range (range of
concentrations inhibiting the growth of 10–90% of progenitors) to
better evaluate the dose–response curve: these ranges were
between 50 and 200 ng ml–1 for 1-h exposure and between 5 and
20 ng ml–1 for 24-h exposure to IDR and its metabolite, between
250 and 2000 ng ml–1 for 1-h exposure and between 25 and 200 ng
ml–1 for 24-h exposure to doxorubicin.
We investigated the inhibitory effect of IDRol present in
patients’ plasma samples by incubating HCB mononuclear cells
(all from the same donor) for 24 h with 1 ml of serum-free IMDM
or 1 ml of undiluted plasma obtained from patients before IDR
infusion and 96, 120 and 144 h after PBPC infusion (corre-
sponding to day of the transplant, day +1 and +2).
We also investigated IDRol cytotoxicity when HCB mono-
nuclear cells were incubated for 24 h in IMDM supplemented with
40 mg ml–1 (mean normal serum level) human serum albumin. In
this case, the medium containing the anthracycline and the
albumin was preincubated without cells at 37°C for 15 min to
allow the binding of the drug.
Clonogeneic assay
Clonogeneic potential was assessed in a semisolid culture system
using a commercially available methylcellulose-based medium
containing 30% FBS, 3 U ml–1 recombinant human (rhu) 
erythropoietin, 50 ng ml–1 rhu stem cell factor, 10 ng ml–1 rhu gran-
ulocyte–macrophage colony stimulating factor (GM-CSF) 
and 10 ng ml–1 rhu interleukin-3 (Stem Cell Technologies,
Vancouver, Canada). Cells were plated in duplicate and incubated
for 14 days in a fully humidified atmosphere with 5% carbon
dioxide at 37°C. Colonies consisting of more than 50 cells were
scored at day 14 under an inverted microscope and classified as
CFU-GM or BFU-E according to previously described criteria
(Coutinho et al, 1993). Only experiments with a minimal cloning
efficiency of 30 CFU-GM per 5 ´ 104 adherent-cell-depleted MNC
were considered.
Patients and treatment
Sixteen patients with poor prognosis Hodgkin’s or non-Hodgkin’s
lymphoma were enrolled in a phase I–II trial of IDR dose-escala-
tion in combination with high-dose melphalan. The median age
was 36 years (range 19–62). Two patients had relapsed Hodgkin’s
disease and 14 had non-Hodgkin’s lymphoma; five received
autologous transplantation for relapse and 11 as consolidation after
first-line chemotherapy.
PBPC were collected after mobilization with cyclophosphamide
7g  m –2 followed by G-CSF 5 mg kg–1 day. After further cycles of
chemotherapy, the myeloablative regimen was administered: IDR
was given intravenously as a continuous infusion at escalating
dosages from 12 to 17 mg m–2 on days –6, –5, –4 before transplant,
followed by melphalan 180 mg m–2 on day –2. The graft, given on
day 0, contained a median of 3.4 ´ 106 CD34+ cells kg–1 (range
2.1–9.6). All patients subsequently received G-CSF 5 mg kg–1 day
from day +5 until neutrophils reached ³ 1 ´ 109 l–1 for 3 consecu-
tive days.
Plasma samples and pharmacokinetics
Blood samples were drawn during and after IDR administration.
Ten millilitres of heparinized blood were drawn 1 h before the
start, then 1, 3, 6, 12, 24, 36, 48, 72 h after the start of IDR infusion
and 0.5, 1, 3, 6, 12, 24, 36, 48, 72, 96, 120, and 144 h after the
end of infusion. Blood samples were centrifuged immediately at
1000 g for 10 min at +4°C. Plasma samples were collected and
stored at –80°C until use. IDR and IDRol plasma concentrations
were measured in each sample by HPLC.
Analysis of data and statistics
Inhibition of colony formation was the proportion of the mean
number of colonies growing from treated cells, compared to the
mean colony number in the control. Dose–response curves were
produced using a standard software program (SAF). The concen-
tration inhibiting the growth of 70% of progenitors (ID70) was
calculated from graphical analysis (Figure 1). The ID70 value was
chosen to ensure accurate prediction of clinically important levels
of drug exposure (Parchment et al, 1998).
Comparison of the growth inhibition of the various progenitors
was performed by fitting a linear regression with logit of inhibition
as a response variable and testing first the effect of HCB versus AP
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BFU-E. The variability between subjects was taken into account.
Correlations were calculated using the Pearson correlation coeffi-
cient (r). Probability values are obtained by transformation of
correlation coefficient ((n22)1/2r/(12r2)1/2) as t2Student with
(n22) degrees of freedom. Differences with a P-value < 0.05 were
considered statistically significant.
RESULTS
In vitro cytotoxicity
The mean cloning efficiency (colonies per 5 ´ 104 adherent-cell-
depleted MNC) of HCB and AP progenitors was comparable,
being respectively 65 ± 23 and 108 ± 56 for CFU-GM, and 50 ± 24
and 99 ± 43 for BFU-E.
Growth inhibition was determined for all haematopoietic
precursors assessable by this assay but the ID70 was calculated
only for CFU-GM and BFU-E since CFU-mix were scored in too
low numbers to allow any analysis.
Cytotoxicity test results are reported in Tables 1 and 2.
Progenitors from both sources demonstrated a similar sensitivity to
the drugs, the differences not being statistically significant. IDRol
showed a toxicity 2–2.5 times lower than IDR. For all drugs,
prolonged exposure was 9–11 times more toxic than 1-h exposure.
The median ID70 for CFU-GM and BFU-E after 24-h exposure
to IDRol in IMDM supplemented with human serum albumin was
15 ng ml–1 (range 9–18) and 12 ng ml–1 (range 7–18) respectively.
These values are not significantly different from the experiments
performed incubating the cells in medium without albumin.
Pharmacokinetic results
In all the 16 patients, IDR was completely cleared from plasma at
the time of transplant, its median half-life being 18.8 h (range
8.9–58.8) (n = 14). In contrast, IDRol levels ranged from 3.3 to
17.4 ng ml–1 (median value 10.2) on the day of PBPC infusion,
from 3.6 to 13 ng ml–1 (median value 8.8) on day +1 and from 3.2
to 11.4 ng ml–1 (median value 6.2) on day +2 (Table 3). IDRol half-
life ranged between 42.5 and 90.2 h (median value 51.2 h, n = 16).
Cytotoxic activity of plasma samples obtained from IDR
treated patients
The mean cloning efficiency of CFU-GM after 24 h exposure was
higher for patients’ plasma both at baseline (101 ± 27 colonies per
5 ´ 104 adherent-cell-depleted MNC) and on the day of transplan-
tation (81 ± 20 colonies) compared to the same cells in serum-free
IMDM (59 ± 15 colonies).
HCB mononuclear cells incubated for 24 h in patients’ plasma
drawn at day 0 showed a median CFU-GM growth inhibition of
21% (range 0–43). With plasma from day +1, the growth inhibi-
tion was still 20% (range 0–40) and on day +2 it fell to 11.5%
(range 0–32) (Table 3). Statistical analysis revealed a weak, not
significant correlation between IDRol plasma levels and the
degree of in vitro cytotoxicity.
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Figure 1 Dose–response curve of AP cells on CFU-GM exposed for 24 h to
IDRol. Median of 5 experiments ( ) and individual data points. ID70
represents the concentration at which 30% of colonies survive.
Table 1 Median ID70 and range (ng ml–1) of IDR, IDRol and the reference compound doxorubicin on HCB and AP after 1-h exposure
HCB (n = 4) AP (n = 5)
CFU-GM BFU-E CFU-GM BFU-E
Idarubicin 70 (55–105) 60 (40–80) 50 (45–60) 45 (35–60)
Idarubicinol 130 (80–170) 120 (105–145) 100 (85–160) 85 (60–130)
Doxorubicin 1300 (800–1700) 1600 (900–2500) 1300 (750–1600) 1800 (750–2100)
Table 2 Median ID70 and range (ng ml–1) of IDR, IDRol and the reference compound doxorubicin on HCB and AP after 24-h exposure
HCB (n = 4) AP (n = 5)
CFU-GM BFU-E CFU-GM BFU-E
Idarubicin 5 (3.5–8) 6 (4–9) 4.5 (2–6) 4 (2–5.5)
Idarubicinol 12 (7–17) 11 (9–16) 12 (9–16) 10 (7–14)
Doxorubicin 120 (90–160) 160 (60–180) 145 (80–190) 160 (120–220)In vitro and in vivo idarubicinol haematotoxicity 527
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Haematopoietic reconstitution
Table 3 shows the pattern of haematopoietic reconstitution for
each patient. All patients achieved a sustained and rapid
haematopoietic recovery. They reached 1 ´ 109 WBC l–1 and 
10  ´ 109 PLT l–1 in a median time of 13.5 days (range 10–19) and
14 days (range 11–38) respectively. A significant negative correla-
tion (P < 0.05) was found between the dose of CD34+ cells kg–1
infused and the median time to 1 ´ 109 WBC l–1 and 10 ´ 109 PLT
l–1. Only a weak, not significant correlation could be found
between IDRol plasma concentration on the day of PBPC infusion,
the grade of colony inhibition and the haematopoietic engraftment.
A significant correlation (P < 0.05) was found between the level of
toxicity observed on CFU-GM with plasma samples drawn on day
+1 and +2 and the time to WBC and PLT recovery.
DISCUSSION
Van Der Lely et al (1989) and Muus et al (1993) reported that the
addition of anthracyclines to a conditioning regimen for bone
marrow transplantation may be associated with a slower
haematopoietic recovery. With this study we wanted to obtain more
information on the toxicity of IDR and IDRol on haematopoietic
progenitors and to investigate if residual IDRol persisting in
patients’ plasma at the time of transplantation, could result in an
inhibition of transplanted PBPC. We also aimed at correlating this
plasma inhibition potential with the time of engraftment.
To obtain data on the sensitivity of haematopoietic progenitors,
we first performed in vitro myelotoxicity experiments testing IDR,
IDRol, and doxorubicin as a reference compound. We used HCB
as a source of haematopoietic progenitors as suggested by Leglise
et al (1996) and Ghielmini et al (1997, 1998). The experiments
with doxorubicin produced results similar to the published ones
(Minderman et al, 1994; Ghielmini et al, 1998). With IDR and its
alcohol metabolite we found a slightly smaller toxicity compared
to reported data (Minderman et al, 1994; Dodion et al, 1997), but
these discrepancies can be explained by different times of expo-
sure and culture conditions. On the other hand the proportion of
cytotoxicity between IDR and IDRol we have observed (IDRol
2–2.5 times less toxic than IDR) agrees with the published data
(Dodion et al, 1987; Minderman et al, 1994). We demonstrated
that the sensitivity of HCB to anthracyclines is similar to that of
PBPC. To our knowledge, only few groups have been using AP as
a substrate for haematotoxicology studies; further experimental
protocols testing other classes of drugs are therefore required to
validate PBPC as a cellular model for haematotoxicology.
Because it was reported that the pattern of toxicity of a drug
on haematopoietic cells in vitro could predict the pattern of
myelotoxicity in vivo (Gribaldo et al, 1996; Parchment et al,
1998), we compared the cytotoxic activity of IDRol-containing
plasma samples to previously constructed IDRol dose–response
curves and correlated it with pharmacokinetic data and time of
engraftment. In accordance with data from other authors (Camaggi
et al, 1992; Robert et al, 1993), pharmacokinetic studies on our
cohort indicated that IDRol persists in plasma for a prolonged time
after IDR administration and it is still present at the time of
haematopoietic progenitors transplant. Plasma samples showed a
median colony inhibition of 21% on the day of transplantation and
lower values in the subsequent 2 days. In contrast, the median
IDRol concentration detected in plasma at the time of PBPC
infusion (10.25 ng ml–1) was able to inhibit the growth of 70% of
CFU-GM progenitors (ID70) in the 24-h in vitro exposure. Despite
that, all patients achieved a rapid and sustained haematopoietic
recovery: no delay or failure of engraftment occurred. Only a weak
correlation was found between IDRol plasma concentration on the
day of PBPC infusion, the grade of in vitro cytotoxicity and the
haematopoietic engraftment. In vitro assessment of IDRol myelo-
toxicity appears not to reflect the situation in vivo and the clinical
relevance of persisting IDRol at the time of stem cell reinfusion
remains unclear.
We observed an important variability among patients
concerning IDRol plasma levels, the cytotoxic potential of plasma
samples and the clinical outcome. We supposed that the variability
in the plasma inhibition activity might be related to differences in
the levels of free IDRol among plasma samples since IDRol is
extensively bound (about 94%) to plasma proteins in vivo
(Camaggi et al, 1992). Nevertheless, we found no evidence that
albumin influence in vitro IDRol cytotoxicity, but the possible
effect of binding to other plasma proteins was not tested.
Table 3 Patient’s characteristics, IDRol plasma levels and CFU-GM growth inhibition
Patient Diagnosis Dose of Activity at time of PBPC Activity on day +1 Activity on day +2 CD34+ cells Time to haematopoietic
no. IDR infusion infused reconstitution (days)
(mg m–2) (ng ml–1) Inhibition (%) (ng ml–1) Inhibition (%) (ng ml–1) Inhibition (%) (´ 106 kg –1) WBC > 1 ´ 109 l–1 PLT > 10 ´ 109 l–1
1 NHL 12 3.3 0 3.6 4 3.2 0 3.7 15 16
2 NHL 12 8.4 25 6.5 21 4.6 n.e.° 5.6 10 11
3 NHL 14 6.6 14 6.4 0 3.8 0 2.1 13 13
4 HD 14 14.2 20 13 n.e.a 11.4 n.e.° 3.5 14 18
5 NHL 14 13.6 16 11.4 18 8 13 2.1 12 12
6 NHL 14 14.4 20 11.7 18 9.4 22 2.9 17 19
7 NHL 14 10.4 34 9.8 36 7.4 32 7.5 13 12
8 NHL 15 17.4 0 11.2 0 9.4 0 9.6 11 11
9 HD 15 13.6 43 6.5 40 5.4 27 2.1 15 15
10 NHL 16 9.2 18 10.4 20 7.8 14 8.2 14 14
11 NHL 16 17.3 26 12.2 22 9.4 12 8.1 12 13
12 NHL 16 11.9 40 9.9 28 6.4 7 3.4 13 n.e.
13 NHL 17 10.1 33 5.4 25 5 10 3.3 16 16
14 NHL 17 7.5 12 5.2 5 3.8 0 4.3 13 13
15 NHL 17 8.2 22 7.9 15 5.1 11 2.4 19 38
16 NHL 17 9.6 37 7.5 24 6.1 16 3.1 16 18
Median 10.25 21 8.85 20 6.25 11.5 3.45 13.5 14
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Other factors not present in our in vitro system may play an
important role in determining the biological activity of the drug
and explaining the lack of in vitro–in vivo correlation: one is the
observed stimulatory activity of patients’ plasma on HCB progen-
itors, possibly due to endogenous growth factors exerting a 
stimulating and protective effect on reinfused haematopoietic
progenitors. Another additional factor present in vivo is the
marrow stromal environment which is crucial in supporting and
regulating the proliferation and differentiation of haematopoietic
progenitors: the extracellular matrix can modulate haematopoietic
cells adhesion and bind regulatory molecules, and the stromal cells
are capable of producing growth factors (Campbell et al, 1988).
Such interaction with the stromal environment may play a role in
determining the in vivo stem cells chemosensitivity.
Taken together, our data indicate that biological and clinical
factors other than the direct toxicity of the drug must be considered
in evaluating IDRol haematotoxicity in vivo. Consequently,
caution must be paid in extrapolating in vitro data to the clinical
situation and further studies are required to better understand the
predictive value of haematotoxicity tests. Additionally, it appears
that plasma drug concentrations on the day of PBPC reinfusion
may be less important than previously believed, in determining the
speed of haematological recovery after stem cell transplantation.
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